What is Nomic?
Nomic Bio operates at the vanguard of the biotechnology sector, providing a seamless protein profiling service that addresses critical bottlenecks in proteomic research. By utilizing advanced DNA nanotechnology, the company's nELISA platform enables the processing of over 10,000 samples per week, offering a turnaround time as short as one week. This capability is transformative for pharmaceutical and biotech entities that require comprehensive, high-fidelity data to inform therapeutic development. Nomic's market position is defined by its ability to bridge the gap between complex biological data and actionable scientific insights, effectively serving as a catalyst for innovation in precision medicine and drug discovery.
How much funding has Nomic raised?
Nomic has raised a total of $59M across 2 funding rounds:
Series A
$17M
Series B
$42M
Series A (2021): $17M with participation from SR One, Lux Capital, and Casdin Capital
Series B (2024): $42M led by Real Ventures, Lux Capital, Avant Bio, and Amplitude Ventures
Key Investors in Nomic
Lux Capital
Lux Capital is a New York based venture capital firm that raises dedicated funds to invest in earlystage and growthstage companies at the intersection of science and technology, backing founders in frontier areas such as AI, robotics, space, defense, biotechnology, and advanced materials from seed through IPO or acquisition.
Avant Bio
AVANT BIO is a leading equity firm focused on advancing life sciences through investments in therapeutic enabling technologies, biomanufacturing tools, machine learning, AI applications, healthtech, and techbio.
Amplitude Ventures
Amplitude Venture Capital deploys a growth model that has successfully been used to build Canadian companies with world-class management teams and scale companies to breakout potential, applying an evidence-based approach to investing in precision medicine.
What's next for Nomic?
With the successful closure of its latest financing round, Nomic is well-positioned to scale its operational capacity and expand its footprint in the competitive proteomics landscape. The strategic deployment of this capital will likely focus on enhancing the throughput of the nELISA platform and broadening its application across diverse therapeutic areas. As the demand for high-throughput, cost-effective proteomic analysis continues to rise, Nomic's ability to maintain its technological edge will be paramount. Future growth will likely involve deepening partnerships with life science vanguards and further integrating machine learning capabilities to refine the predictive power of its protein profiling services, ensuring the company remains a cornerstone of modern biomanufacturing and research tools.
See full Nomic company page
